Fed. Circ. OKs Novartis Loss In Eye Syringe Patent Feud

By Adam Lidgett · September 23, 2024, 6:24 PM EDT

The Federal Circuit has backed a Patent Trial and Appeal Board finding that more than two dozen claims in a Novartis pre-filled eye injection syringe patent weren't patentable....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc.

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

-

Date Filed

January 05, 2023

Recent Articles By Adam

November 18, 2024
Medical Group Wants Justices To Review IP Safe Harbor Fight
November 01, 2024
Jury To Decide Timing Issue In Insulin Patch Trade Secret Row
October 22, 2024
Patent Office Finds Public Engagement Leader
July 11, 2024
Senate Clears Patent Bill Aiming To Lower Drug Prices
June 07, 2024
DC Circ. Undoes Library Of Congress Win In Fair Use Fight
June 06, 2024
8th Circ. Affirms Cigna Noncompete Applies To CVS Hire
May 29, 2024
Greenberg Traurig Adds IP Atty From Eversheds Sutherland
May 20, 2024
Judge Tosses Acuitas' COVID Biotech IP Suit
April 30, 2024
FTC Continues To Target 'Junk' Drug Patents
April 10, 2024
Pharmacy Gets Eli Lilly's Mounjaro Suit Tossed